Literature DB >> 10178656

The selection of data sources for use in modelling studies.

M J Nuijten1.   

Abstract

Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of recommendations for the use of secondary data in modelling studies. In this manuscript, the selection of data sources in modelling studies will be addressed. The objectives of this manuscript are as follows: (i) to present a general strategy on how to determine the appropriateness of a data source for a model; and (ii) to present recommendations on a transparent reporting format for the selection of data sources.

Mesh：

Year:  1998        PMID： 10178656     DOI： 10.2165/00019053-199813030-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


  14 in total

Review 1.  The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings.

Authors:  C Evans
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

2.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

3.  Bias in analytic research.

Authors:  D L Sackett
Journal:  J Chronic Dis       Date:  1979

4.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

5.  A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

Authors:  S A Montgomery; J G Rasmussen; P Tanghøj
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

6.  Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice.

Authors:  T Jefferson; V Demicheli
Journal:  Health Econ       Date:  1995 Sep-Oct       Impact factor: 3.046

7.  Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.

Authors: 
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

8.  The Delphi technique: a methodological discussion.

Authors:  P L Williams; C Webb
Journal:  J Adv Nurs       Date:  1994-01       Impact factor: 3.187

9.  Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study.

Authors:  C Rosenberg; N Damsbo; E Fuglum; L V Jacobsen; S Horsgård
Journal:  Int Clin Psychopharmacol       Date:  1994-03       Impact factor: 1.659

10.  The hazards of using active clinic patients as a source of subjects for clinical studies.

Authors:  A S Detsky; K O'Rourke; P N Corey; N Johnston; S Fenton; K N Jeejeebhoy
Journal:  J Gen Intern Med       Date:  1988 May-Jun       Impact factor: 5.128
View more
  22 in total

1.  Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

Review 2.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

3.  Applications of modelling studies.

Authors:  M J Nuijten; J Starzewski
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

4.  A proposed model for economic evaluations of major depressive disorder.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Jodi Gray
Journal:  Eur J Health Econ       Date:  2011-06-02

5.  The incorporation of potential confounding variables in Markov models.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.

Authors:  Mark J C Nuijten; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].

Authors:  Mark Nuijten; Daniela P Roggeri; Alessandro Roggeri; Paolo Novelli; Thomas S Marshall
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

Review 8.  It's time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies.

Authors:  Oren Shavit; Moshe Leshno; Assaf Goldberger; Amir Shmueli; Amnon Hoffman
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 9.  Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.

Authors:  James E Stahl
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.

Authors:  Cynthia S Palmer; Mark J C Nuijten; Jordana K Schmier; Prasun Subedi; Edward H Snyder
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.